JACOBIO PHARMACEUTICALS
Corporate brand
UnclaimedJacobio Pharma is a biopharmaceutical company focused on developing novel drugs for cancer, with a pipeline targeting six major oncogenic signaling pathways.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Jacobio Pharma is a biopharmaceutical company that develops novel drugs based on its in-house Induced Allosteric Molecule Discovery Platform and iADC Platform. Its pipeline revolves around novel molecular targets in validated cancer pathways, focusing on six major signaling pathways: RAS, RB, MYC, immune checkpoints, tumor metabolism and P53. The company also uses in-house synergistic combinational strategies and has external licensing deals with multinational corporations to expand global market share.
History
The word 'Jacobio' is a combination of the Hebrew name 'Jacob' meaning 'to seize' and 'bio' from biomedical, reflecting the goal to seize development opportunities in life sciences. The company's story includes milestones such as in 2025, Glecirasib obtained NDA in China and Pan-KRAS inhibitor completed first dosage in U.S.; in 2024, published clinical data of glecirasib at ASCO GI and received approval for registrational phase III clinical trial of combination therapy between glecirasib and JAB-3312; in 2023, received IND approval for GUE inhibitor JAB-24114 in China and presented results of glecirasib in combination with JAB-3312 at ESMO.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/jacobio-pharmaceuticals · Editorial policy · How profiles are compiled